D2L Pharma Research Solutions Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 2.88 M
- Company Age 17 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.60 Cr
- Revenue Growth -3.08%
- Profit Growth -36.52%
- Ebitda -142.91%
- Net Worth 4.74%
- Total Assets 10.36%
About D2L Pharma Research Solutions
D2l Pharma Research Solutions Private Limited (DPRSPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 06 July 2007 and has a history of 17 years and seven months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 2.88 M.
The company currently has active open charges totaling ₹2.60 Cr.
Marella Ravikant, Shekhar Gupta, Deepak Harikrishnan, and One other member serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24232TG2007PTC054728
- Company No.
054728
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jul 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at D2L Pharma Research Solutions?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kode Kiran  | Managing Director | 06-Jul-2007 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shekhar Gupta | Whole-Time Director | 18-Jan-2008 | Current |
| Deepak Harikrishnan | Whole-Time Director | 18-Jan-2008 | Current |
| Marella Ravikant | Whole-Time Director | 05-Feb-2010 | Current |
Financial Performance of D2L Pharma Research Solutions.
D2L Pharma Research Solutions Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 3.08% decrease. The company also saw a substantial fall in profitability, with a 36.52% decrease in profit. The company's net worth moved up by a moderate rise of 4.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of D2L Pharma Research Solutions?
In 2023, D2L Pharma Research Solutions had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
D2l Clinical Solutions Private LimitedMarella Ravikant, Shekhar Gupta and 2 more are mutual person
Yobiz Healthcare Solutions Private LimitedShekhar Gupta is a mutual person
N9 Pharmaceuticals Private LimitedKode Kiran is a mutual person
- Alx Biotech Private Limited
Kode Kiran is a mutual person
- Arunachalamm Renewable Energy Private Limited
Kode Kiran is a mutual person
Charges (Loans)
₹26.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 2.60 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Apr 2020 | Others | ₹2.60 Cr | Open |
How Many Employees Work at D2L Pharma Research Solutions?
D2L Pharma Research Solutions has a workforce of 47 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of D2L Pharma Research Solutions, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped D2L Pharma Research Solutions's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
